Reference : Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-I...
Scientific journals : Article
Human health sciences : Endocrinology, metabolism & nutrition
Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women
Alexandersen, P. [> > > >]
Karsdal, M. A. [> > > >]
Qvist, P. [> > > >]
Reginster, Jean-Yves mailto [Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique >]
Christiansen, C. [> > > >]
Elsevier Science Inc
Yes (verified by ORBi)
New York
[en] strontium ranelate ; postmenopausal women ; CTX-II ; type II collagen degradation ; RCT
[en] Objective: Strontium ranelate significantly decreases the risk of osteoporotic fractures. The objective of the present study was to investigate whether strontium ranclate (2 g/day) also affects cartilage brakedown as measured by urinary marker of cartilage degradation, designated CTX-II. Methods: A subgroup of 2617 postmenopausal osteoporotic women (aged 75.7 +/- 4.4 years) were selected from the TROPOS phase III study on the basis of a urinary sampling reported at each visit during the first three years of the study. When included in TROPOS, they were randomized to strontium ranelate or placebo in a double-blind fashion for 3 years. A calcium and vitamin D supplement was also provided to the subjects during the study. A marker of collagen type II degradation (CTX-II) corrected for urinary creatinine (CTX-II/cr.) was assessed at regular intervals throughout the study in 1310 patients in strontium ranelate group and 1307 patients in placebo group. Results: The response in CTX-II depended on time (p < 0.0001), and this time dependency differed statistically significantly between groups (time x treatment) (p < 0.0003). In addition, there was a statistically significant difference between treatments (p < 0.0001). The difference in the response of CTX-II/cr. appeared already after three months, with the strontium ranelate-treated subjects having approximately 15-20% lower values than the placebo-treated subjects for the remaining study period (p < 0.0001). Conclusion: Treatment with strontium ranelate significantly decreases urinary excretion of CTX-II, a marker of cartilage destruction. Further studies are warranted to investigate an effect on cartilage formation and symptoms of osteoarthritis. (c) 2006 Elsevier Inc. All rights reserved.

File(s) associated to this reference

Fulltext file(s):

Restricted access
str rane red.pdfNo commentaryPublisher postprint186.28 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.